0001513162-21-000162.txt : 20211216 0001513162-21-000162.hdr.sgml : 20211216 20211216084948 ACCESSION NUMBER: 0001513162-21-000162 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211216 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211216 DATE AS OF CHANGE: 20211216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMERICA INC CENTRAL INDEX KEY: 0000073290 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 952645573 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37863 FILM NUMBER: 211496113 BUSINESS ADDRESS: STREET 1: 17571 VON KARMAN AVENUE CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9496452111 MAIL ADDRESS: STREET 1: 17571 VON KARMAN AVENUE CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: NMS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19871130 FORMER COMPANY: FORMER CONFORMED NAME: NUCLEAR MEDICAL SYSTEMS INC DATE OF NAME CHANGE: 19830216 FORMER COMPANY: FORMER CONFORMED NAME: NUCLEAR INSTRUMENTS INC DATE OF NAME CHANGE: 19720508 8-K 1 bmra-20211216.htm FORM 8-K Form 8K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

_______________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  December 16, 2021

BIOMERICA, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-37863

95-2645573

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

 

17571 Von Karman Ave. Irvine, California

92614

 

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code:  (949) 645-2111

Not Applicable

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company      ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐


 

1

 

 

Item 2.02              Results of Operations and Financial Condition.

 

On December 16, 2021, Biomerica, Inc. (the “Company”) issued a press release reporting its preliminary financial results for the three months ended November 30, 2021. A copy of the press release is furnished with this Current Report on Form 8-K and attached hereto as Exhibit 99.1.

 

The information furnished under this Item 2.02 and the exhibit attached hereto as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 8.01              Other Events.

 

For the second quarter of fiscal 2022, ended November 30, 2021, the Company expects to report revenue of approximately $4.6 million, an increase of 238% as compared to the second quarter of fiscal 2021 revenues of approximately $1.4 million. The increased revenue was driven primarily by increased demand for the Company’s Covid tests.  The Company also enters its third quarter of fiscal 2022 with over $4.0 million of outstanding unfilled customer orders (backlog).  The increase in backlog is also primarily attributable to the Company’s Covid tests. For the second quarter ended November 30, 2021, the Company also expects to report an operating loss of between $0.9 million and $1.3 million. The Company ended the second quarter with over $7 million of cash on the balance sheet.

 

The Company experienced logistics constraints and significantly higher shipping costs which had a material negative impact on margins and profits during the second quarter.

 

Forward Looking Statements

 

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this Current Report contains statements that are forward-looking, such as statements relating to the Company’s estimated financial results, future revenue and operating margins, demand for the Company’s products, the Company’s ability to fulfill orders, and clinical trials. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company’s tests, InFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company’s products; availability of the Company’s test kits and other products; capacity, resource and other constraints on the Company’s suppliers; dependence on the Company’s third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for the Company’s various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the Company to maintain current operations; the Company’s ability to comply with current and future regulations in the countries where the Company’s products are made and sold and the Company’s ability to obtain patent protection on any aspects of its rapid test technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

 

Preliminary Financial Data


The preliminary financial information included in this Current Report is subject to completion of the Company’s quarter-end close procedures and further financial review. The Company has provided estimates because these results are preliminary and subject to change. Actual results may differ from these estimates as a result of the completion of the Company’s quarter-end closing procedures, review adjustments and other developments that may arise between now and the time such financial information for the period is finalized. As a result, these estimates are preliminary, may change and constitute forward-looking information that are subject to risks and uncertainties. These preliminary estimates should not be viewed as a substitute for full consolidated financial statements prepared in accordance with United States generally accepted accounting principles, and they should not be viewed as indicative of the Company’s results for any future period. The Company’s independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures with respect to these estimated financial results and, accordingly, does not express an opinion or any other form of assurance with respect to these preliminary estimates.

 

 

2

 

 

Item 9.01              Financial Statements and Exhibits.

(d)   Exhibits.

 Number

  

Description

 

 

 

99.1

 

Press Release of Biomerica, Inc., issued December 16, 2021.

 

 

 

 

3

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

BIOMERICA, INC.

 

 

 

 

Date:  December 16, 2021

By:

 

/s/ Zackary S. Irani

 

 

 

Zackary S. Irani
Chief Executive Officer

 

 

 

 

 

 

 

 

4

 

false 0000073290 0000073290 2021-12-16 2021-12-16
EX-99.1 2 exhibit99_1.htm EXHIBIT 99.1 Exhibit 99.1

                                     

Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to approximately $4.6 Million

-      InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022.

 

Irvine, California – December 16, 2021 – Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced certain preliminary financial results for the second fiscal quarter ended November 30, 2021. All figures in this release are approximate due to the preliminary nature of this announcement.

For the second quarter of fiscal 2022, ended November 30, 2021, Biomerica expects to report revenue of approximately $4.6 million, an increase of 238% as compared to the second quarter of fiscal 2021 revenues of approximately $1.4 million. The increased revenue was driven primarily by increased demand for the Company’s Covid tests.  The Company also enters its third quarter of fiscal 2022 with over $4.0 million of outstanding unfilled customer orders (backlog).  For the second quarter ended November 30, 2021, the Company also expects to report an operating loss of between $0.9 million and $1.3 million. The Company ended the second quarter with over $7 million of cash on the balance sheet. The increase in cash during the quarter was primarily attributed to partial prepayments for orders expected to ship during the third quarter.

The Company experienced logistics constraints and significantly higher shipping costs which had a material negative impact on margins and profits during the second quarter.

Biomerica’s Chairman and Chief Executive Officer Zack Irani stated, “We are very encouraged by the heightened demand we’re seeing for our products; particularly for our COVID-related testing products. As the virus continues to present new variants, we anticipate demand for these tests as well as our at-home tests for other diseases to remain strong.   We are also seeing increased interest and demand across our other product lines.  Like most companies, we are contending with supply chain constraints that are negatively impacting our margins. However, the revenue growth we are seeing positions us well for higher operating margins as the worldwide supply chain issues subside.” 

Mr. Irani continued, “Finally, I am pleased to announce that data analysis is underway for our InFoods IBS clinical trial. We believe we’re on track to receive and announce top line results by the end of January, 2022.” 

 

1

About Biomerica (NASDAQ: BMRA) 


Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primary focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

 

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements relating to the Company’s estimated financial results, future revenue and operating margins, demand for the Company's products, the Company's ability to fulfill orders, and clinical trials. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company’s tests, InFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company’s products; availability of the Company’s test kits and other products; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; the Company’s ability to comply with current and future regulations in the countries where our products are made and sold and the Company’s ability to obtain patent protection on any aspects of its rapid test technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.


Preliminary Financial Data


The preliminary financial information included in this press release is subject to completion of Biomerica’s quarter-end close procedures and further financial review. Biomerica has provided estimates because these results are preliminary and subject to change. Actual results may differ from these estimates as a result of the completion of the Company's quarter-end closing procedures, review adjustments and other developments that may arise between now and the time such financial information for the period is finalized. As a result, these estimates are preliminary, may change and constitute forward-looking information that are subject to risks and uncertainties. These preliminary estimates should not be viewed as a substitute for full consolidated financial statements prepared in accordance with United States generally accepted accounting principles, and they should not be viewed as indicative of the Company's results for any future period. Biomerica’s independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures with respect to these estimated financial results and, accordingly, does not express an opinion or any other form of assurance with respect to these preliminary estimates.


2

Corporate Contact:

John Nesbett /Jennifer Belodeau

IMS Investor Relations

203.972.9200

jnesbett@institutionalms.com

 

Source: Biomerica, Inc.

 

3

 

 GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X 02D9)1@ ! 0 0 ! #__@ ?0V]M<')E2!J<&5G+7)E M8V]M<')E%Q45%QXB'1L=(BHE)2HT,C1$1%P!! 0$! 0$! 0$! 8& M!08&" <'!P<(# D)"0D)#!,,#@P,#@P3$100#Q 4$1X7%147'B(=&QTB*B4E M*C0R-$1$7/_" !$( %0#)0,!(@ "$0$#$0'_Q = $ @(# 0$ M !08$!P(#" $)_]H " $! /?P M ,*+CHV,AH3-L=RM#Z M #YYYX26.[+K4H"RU^Q5C/E)FMYU=\]PF]O6?: M$/Y!PZIZ.:91W/T'I.U:FN7KO15)G/5F-^:DQ^@TN $)JZ5RH M&2L,#/T_JLMBI7=&3EZU)%GH 5L0D1,2 B8$B"0 #_\0 M&P$! , P$ $" P4&!P3_V@ ( 0,0 M XNS3+77D.4[;CY] #/JUML-+_ !\SEV[TWR.H ":S$H)1,2 M%K4@ $2 $2 _\0 ,! 04! $# @0%! , ! $" P4&!Q$ M$A,(%!46(3$7,T%08#) 0E%7<(#_V@ ( 0$ 1( _P#JJ>2S:BK #&_U*9IT M_2&G 5/4AVY3S\>>J5]37'2(_P"7C:N7U-J^FCIY=S-DJ>I^I;,+RIO);=$3 M]UE^H40)?%KB[D1?0WU%8F;^<':0^@^W\Y+\(MXX=?5;M\E;JU*[25\[E_9K M9&N\*U45%_K_ (>J^/0_8=5>ZJ\S63QXM@H$LZ?)?=CV.*("_.& B'')]WL? M:]FF'W%5DZVDBFA*0-[R8NRW6JN"JGG6/6TC'_5YE_T;IN-%2TTF# =7(]K) M)='W@0#,9B_I:E27VLD\:B\MZ,[?TIQ\M?&'.*8L#XND]I@Q-O#25M8RR,;% M\I:6G?+*OI\D6S-0REW,,\_VWYUZ[_XIC]:3M.KRS*8*WQH\-L>LKU$-V'6Z MX2<\CFP+H8&+)(B_4,++E"+L;/JEA ? (\4ON\ -/GU7/R%:&U@9.RM=JNS, M%=8.YS7)"C%D6#FO4Z_HD9\#:V0$\-K'RQ=*[")DK-*"MI8;_.%1/^&/\ J$.AFA#V8C)AU5$4X4D5LD,S&R1O\ \-T-I'2T=O;2 MJB-"#FG]<7R>JNX+S0TFK=2R/G0:63=!VM!O\\+L;1FP;)\2L@//DM]+TG41 M(JQP0%I$[Z=0A1\.09$K%G*LIUF]?4/H!@,:RE2=J%V1,2?'C*)]CO,%EB85 M^*FKOO3(L1LFB:,G1])S6-# M,<*M57@@H0[F.W\?IV2W3UK![/7]I@I:$CJ!'7\U0I)>:4&>H+E M02==6-1-HL#2Y88B/\38\^?USH08SMT\9?M:VM>7&/'I-!59BE.N;>7V!CL] MSDFZ5A,[CC]-BLVP P^=X <5'SSJ0]5H5ESU241HQG(65]-=VX8G2Y8KRCV* MTV)GHN(:<>>(N.-\#V.21NCCJX=!>1TCD6L8=,T5]?U2IXSC* MZR9;EQ&VQS%1S)J+G]#0:.YU(?W+[*R]_P [[+C6)M=)/IC1B9"I2F$R1:[ MT6V=4K=H2K:Z1TD+#>%XL^Q-M9YK5"RIY9Y'_P !<7Y:JEW3O"^?%!R[,YS1 ME:D%"WV4Z3>]VSQ=/M*F*HN5G^!A#"/4?&,;'94EFJ'.FJF"L%;H^.XK26;[ MF<^\J;UXTOFK9&P(2>VJ!?*$60L7 MC]TJ\USRBU)6MIB3YK.9Y$CXY]-H)VJVDQALRK^B27&)Z+MHGBZ/5"U58_\ MU@T'#\'2*R6:O?93L\*CX1H!HHX!X61Q,:B-9_O_ *@B[TJ\IVY^3V396N=I MIO5+J0=#K-7TV%GD"BQHC(O6&SN"M*NE35\AVMG=6$J2$VUE?+A-AU^&FC8E MM9+G:ZD'S[+&/-V_' 3'36MQM#P"BMED:FAT>ADW^>MY<\L4 ^?O%F\;3 MDZ#7C&01BPHMSK-,/5XB]U%8=!)'#5SE"D9W6N H1M-K-IIE0.LC*L(?XJT8 M0=_/<5-I6%5-8RTE#H]F%?41U^/66(8([7/9)DNGG#9C+IIX["WOK:J,N52E MZOGKF4&**OLQHBZ>6X@G$[-1E-KOAS5^JG54MJ(V7K%']E4% 5MF=(=4+<_: MVW7*(< PRH"L+.(>GBM9Y\;M+XE0GW=Q8G$@9(:RLPK[L3*NETI*,ZIK"LW!E( K^.F?9WHXLYM9TB:LOKILFD+TV< M2($<$RVZ//9EY6LSJD 'SZQ*NT&DZ?0BVCP5$.E%CM8J:6S_ (E58MN/4V=+ M<5[2G',%,SW2ZF\&EL6U-H%5H ^P999OHU1H+$:JCK;$*8NO_$@G?V(H5"1Y MH72R1I(U4]R9H7]G6=J]/7Y9JG+YD4N3TW+T#515JH)%3]E@J:T9?(]<-$O_ M &C4_L@^!B33[#06!S3$O A@4&J.%_@7.=-A M,C7W!*RR6%%@^E4Q%4TGK: M%50;X4<#/R< CJ2=++/25T8S8QPL;'<-MX1+/.5'1 MC ,@=/*^:H_*^>6C"S9%0*95"PPPQCZ_##Z?)RY$,B*M"?\ ;1^-=D!==ESL M_*2X5DS8UBFM.2D:**_GOM&PBSM6 BS$:.@EO?N_M;SX?..;EQ/4G)_=]Y]K>?#YQS,@&2TTXA0#9@ M:.*E7U;<=+6'4@T6IBK:S0!A"F06?)7$0[)@VEF$DNUJVQ.BXK\ UBP:] @) M)OJ^X\!\?!"TKD'EMWVSVW.-2WU>4TDQ_MCHVF+&*?QD0D.T"2VA4%^ M@CO:X.FY5!3VV:MW6 ?OJI+&=1XN. #7YMK$77_;$VLMF[U1<3,J3Z^V;K(O MQ ,$X:$ZEY&&$_4RV)H?B\JDK"(<-S6#'$_=/EJI9&!1APN_]J?_Q [$ " M 00! @,$!0L$ P ! @, !!$2$P4A%#%1(C)!0A5A@;&R(R0S4&!B<7*2 MH:(08W#"@,/2_]H " $! !,_ /\ RJ>8I_T--?./NA-?2<@_]%+U8C[X14/5 MX3^)14,R3?@6I%4?CUK@1Q_BQJ>WE3_K27";?TT/V1>^X=HX9./<[+@9-0=0 M67;3&V,+4TYC,2W""5BRZGW$.:NIQ!#KY!OJ!JSOBVFWEG(-32&)H?#]GSJ& MR0QI)3(,:!@V2!1F,:P!O<7L&RQKQ1'&BS<46#IW+U]*15XS;2,.(XCLBG)< MYJ+JB.^BC)(&*DG]AA,C/NL@7]RK:4D1I,Q$6[D9V<8(4"OI &?447Y$*/V# M(V!3N1';J?(' ;O4"Z/')&Q&-TU-3_G$/]\-5M^4A'\WQ2EE+1_:C96K9='3 MZY(Z0Y5D89!!]#^QQ_VT+4+-+DSG'*WZ0]L%JE+0",22Z:F.,X!-#Y%N)5LH M_P#!J'F.,!%4U\W#">1GIQ[LTV;I@P_BZ*:;R>X@E:-?LPVQJ7])':C,Y/U- M(5!/U8%(-C ]I!SR.!ZAR:\.G_U5TO(@:RCYF>0#S]NNGPB";VP3J2P) -7+ M!YWGF?PJ;%0!A=#KBG];-!;(!]849H %W)[!$!(RS>0%&U2!KB:(9+D(3M'% MO5_E2@BWB'\WS'ZA M3>;"-<9/['0OHY4,&P#4=^Z#-7-PTKQEAC=,]MQ\#5Y+RAHTS5G?F,5U2Y:Y MPR^1P< U-+NH#ON0@P,49OR#NGJGH<=Q4,NBEFQG3_ !KI,3.77T>634FKY^1?Z!A* M0!5 ] !^H/X7"0I]JX)H]\27"&]D'\Z@!326MU'9R&YD+"3=9T'& PRV*4#O M9 MR:B99(W;0F,J>X8$U?=$6RLS(ZJI6)_!0ESNWL!7)-7:0\\MK(<*\7%(Z]R- M<$@@U?P<'/&L8DY8@228\' :K.&! EI$Y(W+-"B80BKJ*-8Y+: @.<([."I/ MS TT5LAFMH??;VIAIKZO@&K:.(3PV*CO-+RNB@9[8!)/PJTCCX[2"Y7:)I^ M5T.6\]5!8"K;ID3\UQ?,9(C&T/MF54&O&$ J]-NC*W41^;NQBE<:$]B 2]!( M3:VW4Y@,VKE9&8L"=69 R _-3\ X;34M,X-RKH/XD4D%LTL_5;ER/!VTEJD$ M4N5[D_)5U%$TT45M$9IXS@R)W7&'0FD1/!Q7\OE 27W)^!8(5!J\@2*&?P*< MDI1=S,!J"0S( :N8XC9R0(>YWA>31@!DH^KU>1QJ+NSVTYH]'<@9(]EPK?J. M)BCC/Q4CR-&^F'X6%/>W#?>]2CD_'FHXE7[A^I3%H+>VB0JR;;'?D)S1M,E( MSH./CY._9<4O0+2 2P1=N,2*24K@P$F1-!,9-N^!Y#%<'&+5)'W= VS;DUX" M"60).(+ $]F0$$C'F:B@#1I!!(K\2("@"D+K4:@F*2%Q( MC!3V(!49%0V9AMTL;283&WBA,K$_$)5*DA05SBO#9$"?//[XV+> ME>'VX(_FG]\;%O2C;[<$?S3^^-B:ZETJ'J M7).@TQ5ETJ"P@DFO46(,%@\A&@P-MF]6J3H]M/U!9I1DHEY-OI$K^TN$W'P: MH^F)XMI;DC%Q/)/)-RR+W'<8Q72+#Z,M],':4Q(RAPFM=4$3RK M]+S=*N;05"@N:F8 !3RDFDX7FW/"-M%=;C%59'!$@3!-)P[,?+?"6R3?697T MBFX5EHH9Q;0$L!JN*)TF#S-'AF4HM,QM@7"=$W%&J#&U'A'$ =\=@=92)'," M3VI\#(6T]X:71" Y1U;3/K%7,'+M8UO+>W%ER "?>B6&Y4$4'4_"+>@7+9N3 MHU#5'I--QC%_-W\DNS(R%506@K#:!YYFLWBN%F8SXBFY:0&UH;3,JBQ!WJQQ M/%Q,)\2QXC-I=@Y$2[C3V %'C6(+]F\B.&?0V2T;DHNRK[$\ZRN)X^0N.+>0 MR+;M!2&L*\L=R9--Q;'\?AZBRKXUBVJMKM@M/4BFXWB-9?&F]I>U=4W")8,[ M3WVJR_#;*@.]^YYM3 #2K Y(']4/-^WT4CYDP1VH05+3UH'=A_&)[T3I#,>2 MB31\L@].?:N5?RG:*&Y@4#JGYD?\H;Q[F*D1/2)^#E09GT([&N1+==OH(% 1 M '0,!\F,FH@:>FWTJ.?N=7>B 5*GD:.\SUF>\_>CN9[_ -_>O6AM$=*@"/;[ MS7I[ BHD1[$=C4D\_C/_Q U$0 " 0,# 0,)!P4 ! @, !!$%$C$A M05%A!A 3%"*!D:'1!Q4R0%!R@B,P0V!Q_]H " $# 0$_ /\ ;#J]D$:3<_HU M8H7V-MR#CFOO:QW%%E+.'V;54DD^%-JUE'Z42NR-&H9E=2#@],@4^I6<=HEZ M\P$#<-CFEU:S=BJ&1R "=L;'&X9'%)J]GF0"-G,8&_\ IN=N>O6H_*+2A_CM MW&T-U#\$X'!YJ#7]*:6.&;1HM[C*AC-'N _E5KKGD5=73V<^DW41NML(M.UVXM[AN(KE5S[N,UJOV;ZU81O-:/'>1J,D)E7Q^TT002" M,$'!'Z/*',4@CQO*G;GOI=&N_5(;<(JNKAF7R73(*S%,*.@&!2Z1<>KW[&5DN9Y&9=CD+CL!I-"O%F2YVPDI+&PC M!P"J+]:GCU.=LI'#&-NU<^TP)Y8&H]"G@NK&XM"[B/"IDYK4/M+2"T2ST:WDD=8A'ZS<> QNVCDT[M([R.3_? M)W8Y )'B>ZLC&[W?+)H^S^+@'KX#%'(8+CD5V*1USG%@R: M/3'_ &B<>X9->'Y-79?PG%>FEX](WQHDGDD_DOJ#\*(!&/$GXT?:SGMVD_Q MXKD[NWK\Z[O 8H9!#=HH=,8[,?+'TH=./,>H(/;YN_QQ7;GMR#\*P!^L_P#_ !V0$! end EX-101.SCH 4 bmra-20211216.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.DEF 5 bmra-20211216_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 bmra-20211216_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT EX-101.PRE 7 bmra-20211216_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 bmra-20211216_htm.xml IDEA: XBRL DOCUMENT 0000073290 2021-12-16 2021-12-16 8-K 2021-12-16 BIOMERICA, INC. DE 001-37863 95-2645573 17571 Von Karman Ave Irvine CA 92614 949 645-2111 false false false false false false 0000073290 XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information
Dec. 16, 2021
Document Information Line Items  
Entity Registrant Name BIOMERICA, INC.
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0000073290
Document Period End Date Dec. 16, 2021
Entity Emerging Growth Company false
Entity Incorporation, State or Country Code DE
Entity File Number 001-37863
Entity Tax Identification Number 95-2645573
Entity Address, Address Line One 17571 Von Karman Ave
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92614
City Area Code 949
Local Phone Number 645-2111
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #=&D%,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " W1I!35V*3^.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OIVG+@J&;B^))07!!\1:2V=U@TX9DI-VW-XV[740?P&-F_GSS M#4RGO=!CP.

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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.biomerica.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports bmra-20211216.htm bmra-20211216.xsd bmra-20211216_def.xml bmra-20211216_lab.xml bmra-20211216_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bmra-20211216.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "bmra-20211216_def.xml" ] }, "inline": { "local": [ "bmra-20211216.htm" ] }, "labelLink": { "local": [ "bmra-20211216_lab.xml" ] }, "presentationLink": { "local": [ "bmra-20211216_pre.xml" ] }, "schema": { "local": [ "bmra-20211216.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd" ] } }, "elementCount": 22, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bmra", "nsuri": "http://www.biomerica.com/20211216", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "bmra-20211216.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.biomerica.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "bmra-20211216.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "bmra_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.biomerica.com/20211216", "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomerica.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r3": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r4": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001513162-21-000162-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001513162-21-000162-xbrl.zip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